Literature DB >> 10716661

Recent insights into the molecular pathogenesis of Huntington disease.

B R Leavitt1, C L Wellington, M R Hayden.   

Abstract

Huntington disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the HD gene resulting in expression of an uninterrupted polyglutamine stretch within the N-terminus of its protein product huntingtin (htt). In this article we review the clinical, genetic, and neuropathological features of HD and discuss recent insights into the pathogenesis of HD. Examining the role of CAG repeat size on age of onset and penetrance in HD using a refined database of human HD patients has provided further support for the importance of the CAG repeat in the pathogenesis of HD and information leading to a predictive model for the likelihood of being affected by a specific age for a particular CAG expansion. In a YAC transgenic mouse model that replicates key elements of the HD phenotype, the development of selective striatal neurodegeneration is coincident with cleavage of htt and translocation of the N-terminal htt fragment into the nucleus. We also review in vitro evidence that htt is a substrate for cleavage by a group of cysteine proteases involved in apoptotic death-the caspases, and that caspase cleavage of htt results in the generation of a toxic N-terminal fragment. Inhibiting caspase cleavage of huntingtin eliminates the toxicity of the mutant htt protein. These results suggest that cleavage of huntingtin resulting in production of a truncated N-terminal fragment may be a crucial step in the pathogenesis of Huntington disease and that inhibition of this process may be a potential therapeutic strategy for this currently untreatable disorder.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10716661     DOI: 10.1055/s-2008-1040853

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  13 in total

1.  The origins of human disease: a short story on "where diseases come from".

Authors:  Johan P Mackenbach
Journal:  J Epidemiol Community Health       Date:  2006-01       Impact factor: 3.710

Review 2.  Redox proteomics in some age-related neurodegenerative disorders or models thereof.

Authors:  D Allan Butterfield; Hafiz Mohmmad Abdul; Shelley Newman; Tanea Reed
Journal:  NeuroRx       Date:  2006-07

3.  Quantifying Huntingtin Protein in Human Cerebrospinal Fluid Using a Novel Polyglutamine Length-Independent Assay.

Authors:  Valentina Fodale; Roberta Pintauro; Manuel Daldin; Maria Carolina Spiezia; Douglas Macdonald; Alberto Bresciani
Journal:  J Huntingtons Dis       Date:  2022

Review 4.  The ubiquitin-proteasome pathway in Huntington's disease.

Authors:  Steven Finkbeiner; Siddhartha Mitra
Journal:  ScientificWorldJournal       Date:  2008-04-20

5.  Early onset Huntington disease: a neuronal degeneration syndrome.

Authors:  Sara Seneca; Domique Fagnart; Kathelijn Keymolen; Willy Lissens; Daniele Hasaerts; Sara Debulpaep; Brigitte Desprechins; Inge Liebaers; Linda De Meirleir
Journal:  Eur J Pediatr       Date:  2004-12       Impact factor: 3.183

6.  Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.

Authors:  C Dirk Keene; Cecilia M P Rodrigues; Tacjana Eich; Manik S Chhabra; Clifford J Steer; Walter C Low
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

7.  A common motif targets huntingtin and the androgen receptor to the proteasome.

Authors:  Shweta Chandra; Jieya Shao; Jennifer X Li; Mei Li; Frank M Longo; Marc I Diamond
Journal:  J Biol Chem       Date:  2008-06-27       Impact factor: 5.157

8.  Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice.

Authors:  Michelle Gray; Dyna I Shirasaki; Carlos Cepeda; Véronique M André; Brian Wilburn; Xiao-Hong Lu; Jifang Tao; Irene Yamazaki; Shi-Hua Li; Yi E Sun; Xiao-Jiang Li; Michael S Levine; X William Yang
Journal:  J Neurosci       Date:  2008-06-11       Impact factor: 6.167

Review 9.  Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.

Authors:  Renbao Chang; Xudong Liu; Shihua Li; Xiao-Jiang Li
Journal:  Drug Des Devel Ther       Date:  2015-04-15       Impact factor: 4.162

10.  Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay.

Authors:  Valentina Fodale; Roberto Boggio; Manuel Daldin; Cristina Cariulo; Maria Carolina Spiezia; Lauren M Byrne; Blair R Leavitt; Edward J Wild; Douglas Macdonald; Andreas Weiss; Alberto Bresciani
Journal:  J Huntingtons Dis       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.